[Image from VitalConnect]

[图片来自VitalConnect]

VitalConnect

维塔尔康nect

announced today that it closed a $100 million financing through a combination of equity and debt capital.

今天宣布，通过股权和债务资本的组合完成了一轮1亿美元的融资。

New investor Ally Bridge Group led the financing, with significant participation coming from existing investors. Those include EW Healthcare Partners, MVM and Revelation Partners. Trinity Capital provided the debt financing.

新投资者Ally Bridge Group领投了本轮融资，现有投资者也积极参与，其中包括EW Healthcare Partners、MVM和Revelation Partners。Trinity Capital提供了债务融资。

In conjunction with the financing, the company added Steven Plachtyna from Ally Bridge Group and Eric Shiozaki from Revelation Partners.

公司结合此次融资，新增了来自Ally Bridge Group的Steven Plachtyna和来自Revelation Partners的Eric Shiozaki。

VitalConnect develops the VitalPatch biosensor that monitors patients and detects multiple health problems. According to the company, the platform reduces hospital workloads by enabling home monitoring. Patients who prefer to move freely could use the comfortable, state-of-the-art cardiac monitoring device.

VitalConnect开发了VitalPatch生物传感器，用于监测患者并检测多种健康问题。据公司称，该平台通过启用家庭监测来减少医院的工作量。喜欢自由活动的患者可以使用这款舒适、尖端的心脏监测设备。

It has demonstrated the same effectiveness and quality as existing hospital- or home-based devices..

它已证明与现有的医院或家庭设备具有相同的效果和质量。

VitalPatch, the company’s flagship product, is a small, easy-to-wear biosensor that monitors parameters including heart rate, respiration rate and body temperature. It also detects arrhythmia. The VitalPatch works in conjunction with VistaCenter, a cloud-based program. VistaCenter shows patient-generated data in real time and enables notifications 24/7..

VitalPatch是该公司的旗舰产品，是一种小型、易于佩戴的生物传感器，可监测包括心率、呼吸频率和体温在内的参数，还可以检测心律失常。VitalPatch与基于云的程序VistaCenter协同工作。VistaCenter实时显示患者生成的数据，并实现全天候通知。

“Four years after our commercial launch, VitalConnect has grown to be a leader in ambulatory cardiac monitoring,” said Peter Van Haur, VitalConnect CEO. “Our best-in-class proprietary biosensor, coupled with the live streaming of eight vital signs and biometric parameters over a seven-day wear period, sets VitalConnect apart from the competition.

“在我们商业化推出四年之后，VitalConnect 已成长为动态心脏监测领域的领导者，” VitalConnect 首席执行官 Peter Van Haur 表示。“我们一流的专有生物传感器，加上七天佩戴期内实时传输的八个生命体征和生物识别参数，使 VitalConnect 与竞争对手区分开来。

Additionally, we continue to develop our in-patient remote patient monitoring offering in close collaboration with some of the leading healthcare facilities in the US. With the support of Ally Bridge and Trinity Capital, in addition to our existing investors, we are excited to expand our commercial presence, providing more patients with access to our life-saving technology.”.

此外，我们继续与美国一些领先的医疗机构密切合作，开发我们的住院患者远程患者监测产品。在Ally Bridge和Trinity Capital以及我们现有投资者的支持下，我们很高兴扩大我们的商业版图，让更多患者能够使用我们的救命技术。"